Agios Pharmaceuticals (AGIO) Cash & Equivalents (2012 - 2026)

Agios Pharmaceuticals has reported Cash & Equivalents for 15 years, with the latest figure at $113.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 43.86% year-over-year to $113.6 million; the trailing twelve-month figure through Mar 2026 stood at $113.6 million (up 43.86% YoY), and the FY2025 full-year result was $89.1 million, up 16.9% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $113.6 million, up from $89.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $253.7 million in Q3 2024, with the low at $64.3 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $103.5 million across 5 years, with a median of $88.5 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 95.76% — and 2024, when it soared 294.4%.
• Agios Pharmaceuticals' Cash & Equivalents stood at $139.3 million in 2022, then slumped by 36.66% to $88.2 million in 2023, then declined by 13.56% to $76.2 million in 2024, then climbed by 16.9% to $89.1 million in 2025, then advanced by 27.45% to $113.6 million in 2026.
• The last three Cash & Equivalents figures came in at $113.6 million (Q1 2026), $89.1 million (Q4 2025), and $92.7 million (Q3 2025), per Business Quant data.